Clinical Features, Treatment, and Outcomes for Oropharyngeal Adenoid Cystic Carcinoma: A Systematic Review.

Otolaryngol Head Neck SurgJun 29, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)Oncology (Medical)Open access

Gabriel A Hernandez-Herrera, Katelyn S Rourk, Lazaro R Peraza et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 44 studies involving 195 patients with oropharyngeal adenoid cystic carcinoma to describe clinical features, treatments, and outcomes. The findings indicated that 22.3% of patients had positive lymph nodes at diagnosis, and long-term survival rates showed 3-year overall survival between 71.5% to 100%.

Key findings

  • The female-to-male ratio was 1.7:1 among patients.
  • 22.3% of patients had positive lymph nodes at diagnosis.
  • 3-year overall survival rates ranged from 71.5% to 100%.
  • 36% of patients with disease progression developed distant metastases, primarily to the lungs.

Why it matters

Understanding the clinical features and outcomes of oropharyngeal adenoid cystic carcinoma can aid clinicians in early diagnosis and treatment planning, potentially improving patient management and survival rates.

Source

Published in Otolaryngol Head Neck Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.